Navigation Links
Treating sleep disorders in people with traumatic brain injury may not eliminate symptoms
Date:4/14/2009

Westchester, Ill. A study in the April 15 issue of the Journal of Clinical Sleep Medicine is the first to assess the effectiveness of treating sleep disorders in adults with a traumatic brain injury (TBI). Results indicate that treatment may result in the objective resolution of the sleep disorder without improvements in daytime sleepiness or neuropsychological function.

Results show that in brain-injured subjects with obstructive sleep apnea (OSA), three months of treatment with continuous positive airway pressure (CPAP) therapy dramatically reduced the severity of OSA from 31.4 to 3.8 apneas and hypopneas per hour of sleep; however, there was no demonstrable improvement in measures of daytime sleepiness. Participants experienced no significant changes in measures of mood, quality of life and cognitive performance after treatment for a sleep disorder.

According to principal investigator Richard J. Castriotta, M.D., director of the division of Pulmonary, Critical Care and Sleep Medicine at the University of Texas Health Science Center in Houston, researchers were not surprised by the fact that patients with sleep disorders had more severe injuries; however the lack of improvement in excessive sleepiness and neuropsychological testing after treatment was unexpected.

"The TBI patients with sleep apnea and no improvement in sleepiness may have had a combination of pre-existing sleep apnea and posttraumatic hypersomnia, causing sleepiness after the injury," said Castriotta. "These patients may need stimulant therapy in addition to CPAP in order to improve symptoms."

The study involved 57 adults with an average age of 39 years who had suffered a traumatic brain injury at least three months earlier (average 68 months). Seventy-seven percent of the injuries (44) were incurred as a result of a motor-vehicle accident; other causes were assault, a fall or a falling object. Sixty-one percent of the subjects (35) were free of a sleep disorder, while 23 percent (13) had OSA, 7 percent (4) had periodic limb movements in sleep (PLMS), 5 percent (3) had narcolepsy without cataplexy and 3 percent (2) had post-traumatic hypersomnia.

Participants underwent objective evaluation by overnight polysomnography to detect the presence of sleep disorders, and both objective and subjective tests were used to measure daytime sleepliness, mood, quality of life and cognitive performance. Subjects who were diagnosed with OSA received individualized treatment with CPAP therapy while those suffering from narcolepsy, post-traumatic hypersomnia and PLMS received predetermined dosages of medications that were not adjusted after assessment.

According to the authors, research has shown that some OSA patients have residual hypersomnia despite adequate CPAP therapy, which may explain the lack of improvement in measures of daytime sleepiness. Castriotta stated that the study illustrates how difficult it can be to measure the burden of sleep disorders in people with traumatic brain injuries.


'/>"/>

Contact: Kelly Wagner
kwagner@aasmnet.org
708-492-0930
American Academy of Sleep Medicine
Source:Eurekalert

Related medicine news :

1. Study reports success in treating a rare retinal disorder
2. Treating HIV earlier to decrease the risk of death
3. Cellular target may prove useful in treating deadly brain tumors
4. Treating Complicated Grief -- New NIMH Study Seeks 200 Older Adults Suffering from Unrelenting Symptoms of Complicated Grief for Participation in Non-Drug Clinical Trial
5. New Guidelines for Treating Heart Failure
6. Focus on treating malnutrition in cancer patients, researchers say
7. Less is more when it comes to treating high blood pressure
8. New Mexico Doctors Now Treating Brain and Prostate Cancer With RapidArc Radiotherapy Technology
9. Is telmisartan effective in treating non-alcoholic steatohepatitis?
10. Vitamin A signals offer clues to treating autoimmunity
11. Treating drug-addicted doctors is good medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... Milwaukee, WI (PRWEB) , ... October 13, 2017 , ... ... movement in medicine known as “patient engagement.” The patient is doing more than filling ... research partners. , “There is an increasing emphasis in health care and research ...
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected ... Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the position ... the end of 2018. Upon assuming the role of President and CEO on January ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: